临床试验资讯研究交流群（点击）肿瘤精准治疗的概念不只是基因检测找目前的靶向药。精准治疗的理念在于找到驱动肿瘤发生的原因——驱动基因突变。并使用目前的药物来组合治疗。对于肺癌患者来说ALK融合基因突变是钻石突变，很多患者通过ALK融合突变获得了长期获益 ...

Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

The albumin-to-alkaline phosphatase ratio (AAPR) has emerged as a promising, non‐invasive biomarker for stratifying cancer prognosis. By combining two routinely measured serum parameters, AAPR offers ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...

CHICAGO -- Five-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena) progression-free survival (PFS) benefit in ALK-positive non-small cell lung cancer (NSCLC). In the ...

AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...